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Abstract 
The present investigation deals with the formulation, optimization and 
evaluation of sodium alginate based In situ gel of Clarithromycin and 
Metronidazole Benzoate. Sodium alginate used as a polymer and CaCO3 was 
used as a cross-linking agent. The In situ formulation exhibited well, 
viscosity, drug content and sustained drug release; this study reports that oral 
administration of aqueous solutions containing sodium alginate results in 
formation of In situ gel, such formulations are homogenous liquid when 
administered orally and become gel at the contact site. The results of a 32 full 
factorial design revealed that the concentration of sodium alginate and 
concentration of CaCO3 significantly affected the dependent variables Q1, 
Q12 and T80. These In situ gels are, thus, suitable for oral sustained release of 
Clarithromycin and Metronidazole Benzoate. 
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Introduction  
Helicobacter pylori are also the first bacterium to be 
classified as a definite carcinogen by the World 
Health Organization’s. H. pylori are the only known 
organism capable of colonizing the harsh 
environment of the human stomach. It is associated 
with the development of serious gastro duodenal 
disease—including peptic ulcers, gastric lymphoma 
and acute chronic gastritis. And also single antibiotic 
therapy is not effective for the eradication of H. pylori 
infection in vivo. This is because of the low 
concentration of the antibiotic reaching the bacteria 
under the mucosa, instability of the drug in the low 
pH of gastric fluid and short residence time of the 
antibiotic in the stomach. Triple therapy for treatment 
of H. pylori includes Proton pump inhibitor,  
Clarithromycin (500 mg), and Metronidazole (400 
mg) or amoxicillin (1 g) twice a day. Metronidazole is 
broad  spectrum  of  antiprotozoal  and   anti-bacterial  
 
activity. It absorbed completely and promptly after 
oral intake Clarithromycin is semisynthetic macrolide 
antibiotic derived from erythromycin .that is active 
against a variety of microorganisms. It is effective 
against Mycobacterium avium complex (MAC) and is 
used for the treatment of H. pylori-associated peptic 
ulcer disease One way to improve the efficacy in 
eradicating the infection is to deliver the antibiotic 
locally in the stomach. Better stability and longer 
residence time will allow more of the antibiotic to 
penetrate through the gastric mucus layer to act on H. 
pylori1. 
In situ gel forming drug delivery is a type of 
mucoadhesive drug delivery system. In situ gel 
forming drug delivery systems are a revolution in oral 
drug delivery. These hydrogels are liquid at room 
temperature but undergo gelation when in contact 
with body fluids or change in pH. These have a 
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characteristic property of temperature dependant and 
cation induced gelation.  
The main objectives are preparation and evaluation of 
In situ gelling system of Clarithromycin and 
Metronidazole Benzoate based on sodium alginate 
that retains in the stomach by adhere with gastric 
wall. Provides an increased gastric residence time 
resulting in prolonged drug delivery in 
gastrointestinal tract. 
 
Experimental Methodology 
a) Materials 
Metronidazole benzoate (MTB) and Clarithromycin 
(CLR) were gifted by Lincoln Pharmaceuticals Ltd. 
(India). HPMC was gifted by K100M Shin-Etsu 
Chemical Corporation Ltd. Sodium alginate and 
Calcium carbonate was purchased from S. D. Fine 
Chemicals LTD. Mumbai, India. Xanthan gum, 
Aerosil, Sodium Methylparaben, Sodium 
Propylparaben and Sorbitol  were purchased from 
Shital Chemicals Ltd. 
 
b) Differential Scanning Calorimetry (DSC) 
studies 
DSC study was carried out using DSC-60 instrument 
(M/s Shimadzu) to check the matrix formation as well 
as the compatibility of ingredients. DSC thermograms 
of pure drugs (CLR & MTB) and excipients were 
taken for their identical endothermic reaction. Further 
their physical mixtures of drugs and polymers were 
also studied for their interactions2. Finally, physical 
mixture of all above ingredients was scanned for 
DSC. DSC thermograms were shown in figure 1. 
 
c) Preparation of In situ Gel  
First of all, active material (CLR and MTB) were 
passed from 60# sieve while other inactive 
ingredients were passed form 40# sieve. In around 
35% water, dissolve HPMC K 100M. Then add 
calcium carbonate and active material to it while 
stirring so that there was proper and homogenous 
dispersion of the drug. Take around 30% water in 
other beaker and heat to NMT 60°C on hot plate and 
to it dissolve sodium alginate. Then add Xanthan gum 
to dissolved sodium alginate and make it dissolve. 
Cool it to 40°C.Add step 1 to step 2 or vice-versa. 
Mix well. In around 5% water, dissolve sodium 
methyl paraben, sodium propyl paraben and 
sweetener and after cooling to 40°C add to above 
mixture of step 3 and mix well.  
 
 
 
Figure 1. Results of Differential Scanning 
Calorimetry (DSC) Analysis Drug (CLR) (A), 
CLR + HPMC K100M (B), CLR+ Sodium alginate 
(C), Metronidazole benzoate (MTB) (D), 
MTB+ HPMC K100M (E), MTB+ Sodium alginate 
(F), CLR+ MTB(G) and Drugs(CLR +MTB)  + 
Polymers + CaCO3 (H). 
 
In around 5% of water, make slurry of Aerosil and 
add to above mixture of and mix well. Add 10% 
Sorbitol with constant stirring to above mixture of 
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step 5. In around 0.6% water, dissolve color and filter 
this color solution through muslin cloth and add to 
above mixture and mix well. Dissolve menthol in 
flavor and add to above mixture and mix well. Make 
up volume to 100% with distilled water. Finally, stir 
well. 
 
 
 
Figure 2: Contour plot showing effect of X1 and X2 
on Q1 for CLR 
 
d) Optimization by using 32 full factorial designs 
It is desirable to develop an acceptable 
pharmaceutical formulation in shortest possible time 
using minimum number of man-hours and raw 
materials. Traditionally pharmaceutical formulations 
are developed by changing one variable at a time 
approach. The method is time consuming in nature 
and requires a lot of imaginative efforts. Moreover, it 
may be difficult to develop an ideal formulation using 
this classical technique since the joint effects of 
independent variables are not considered. It is 
therefore very essential to understand the complexity 
of pharmaceutical formulations by using established 
statistical tools such as factorial design. In addition to 
the art of formulation, the technique of factorial 
design is an effective method of indicating the 
relative significance of a number of variables and 
their interactions.  
The number of experiments required for these studies 
is dependent on the number of independent variables 
selected. The response (Yi) is measured for each trial. 
 
2
222
2
111211222110 XbXbXXbXbXbbY +++++=    ……… (1) 
 
Where Y is the dependent variable, b0 is the 
arithmetic mean response of the nine runs and bi is the 
estimated coefficient for the factor Xi. The main 
effects (X1 and X2) represent the average result of 
changing one factor at a time from its low to high 
value. The interaction terms (X1X2) show how the 
response changes when two factors are 
simultaneously changed3. 
 
 
 
Figure 3: Contour plot showing effect of X1 and X2 
on Q12 for CLR 
 
A 32 randomized full factorial design was utilized in 
the present study. In this design two factors were 
evaluated, each at three levels, and experimental trials 
were carried out at all nine possible combinations. 
The design layout and coded value of independent 
factor is shown in Table 1. The factors were selected 
based on preliminary study. The concentration of 
Sodium alginate (X1) and concentration of HPMC K-
100M (X2) were selected as independent variables.  
The selected dependent variables are given below:  
Y1 = Cumulative percentage release (CPR) at 1 hr 
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Y2 = Cumulative percentage release (CPR) at 12 
hr 
Y3 = Time required for 80% of drug release 
(T80%) 
 
e) Evaluations 
1. pH measurement   
The pH was measured in each of the solution of 
sodium alginate based In situ solutions, using a 
calibrated digital pH meter at 27°C. The 
measurements of pH of each data were in triplicate 
and the average values are given in Table 1. 
 
 
Table 1: Optimization of SR suspension formulation using 32 full factorial designs 
 
 
 
2. Determination of viscosity 
Viscosity of the samples was determined using a 
Brookfield digital viscometer (Model no LVDV 
2P230) with spindle number 1. The sample 
temperature was controlled at 25±1°C before the each 
measurements. The viscosity of the solutions prepared 
in water was determined at ambient condition using 2 
ml aliquot of the sample. Increasing the concentration 
of a dissolved or dispersed substance generally gives 
rise to increasing viscosity (i.e. thickening), and also 
as molecular weight of a solute increases viscosity 
increases4. 
 
3. Determination of drug content 
Standard preparation 
(A) For CLR 
Weigh accurately about 50mg of CLR Reference 
Standard & transfer it to 25ml volumetric flask. Add 
about 10ml of methanol & sonicate to dissolve. Make 
up the volume with methanol. Take 10ml of this stock 
solution to a 50-ml volumetric flask, dilute with 
Mobile phase to volume, and mix. Pass a portion of 
this solution through a 0.5mvm or finer porosity, and 
use the filtrate as the standard preparation. 
 
 
 
32 full factorial design for CLR 32 full factorial design for MTB 
Independent 
variable Dependent variable 
Independent 
variable 
Dependent 
variable 
Formulation 
codes 
 X1 X2 Q1 Q12 T80 
Formulation 
codes 
 X1 X2 Q1 Q12 T80 
F1 -1 -1 28.3 98.87 8.6 F1 -1 -1 35.38 98.91 8.3 
F2 -1 0 26.82 98.46 9 F2 -1 0 33.2 98.51 8.8 
F3 -1 +1 25.86 97.89 9.2 F3 -1 +1 32.33 97.91 9.1 
F4 0 -1 25.83 99.57 9.1 F4 0 -1 32.29 99.62 9 
F5 0 0 25.36 98.15 9.3 F5 0 0 31.7 98.13 9.1 
F6 0 +1 24.82 95.52 9.6 F6 0 +1 31.02 95.42 9.4 
F7 +1 -1 24.66 96.89 9.3 F7 +1 -1 30.82 96.6 9.2 
F8 +1 0 23.08 93.78 9.6 F8 +1 0 28.85 93.5 9.4 
F9 +1 +1 22.29 91.2 9.8 F9 +1 +1 27.86 91.33 9.7 
Translation of coded levels in actual units 
Real Value Real Value Independent 
Variables Low  (-1) Medium (0) 
High 
(+1) 
Independent 
Variables Low  (-1) Medium (0) 
High  
(+1) 
Sodium alginate 
(X1) 
1.25 % 1.5 % 1.75 % Sodium alginate (X1) 
1.25 % 1.5 % 1.75 % 
HPMC K100 M 
(X2) 
0.4 % 0.6 % 0.8 % HPMC K100 M (X2) 
0.4 % 0.6 % 0.8 % 
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(B) For MTB 
Weigh accurately about 64 mg of MTB Reference 
Standard & transfer it to 25ml volumetric flask. Add 
about 10ml of methanol & sonicate to dissolve. Make 
up the volume with methanol. Take 10ml of this stock 
solution to a 50-ml volumetric flask, dilute with 
Mobile phase to volume, and mix. Pass a portion of 
this solution through a 0.5mcm or finer porosity, and 
use the filtrate as the standard preparation. 
 
 
 
Figure 4: Contour plot showing effect of X1 and X2 
on T80% for CLR 
 
Sample preparation 
Transfer an accurately measured 40ml of the 
suspension, with the aid of about 330ml of 0.067 M 
dibasic potassium phosphate to a 1000-ml volumetric 
flask containing about 50ml of 0.067M dibasic 
potassium phosphate. Shake by mechanical means for 
30minutes, dilute with methanol to volume, and mix. 
Sonicate for about 30 minutes, and allow cool. Dilute 
with methanol to volume, add a magnetic stirrer bar, 
and stir for 60 minutes, allow settle and transfer an 
accurately measured 10ml of the clear supernatant to 
a 50-ml volumetric flask, dilute with mobile phase to 
volume, mix and pass through a filter having a 0.5-
mcm or finer porosity. Use the filtrate as the Sample 
solution. 
 
4. In-vitro gelling capacity  
To evaluate the formulations for their in-vitro gelling 
capacity by visual method, colored solutions of in situ 
gel forming drug delivery system were prepared. The 
in-vitro gelling capacity of prepared formulations was 
measured by placing five ml of the gelation solution 
(0.1N HCl, pH 1.2) in a 15 ml borosilicate glass test 
tube and maintained at 37±1ºC temperature. One ml 
of colored formulation solution was added with the 
help of pipette. The formulation was transferred in 
such a way that places the pipette at surface of fluid in 
test tube and formulation was slowly released from 
the pipette. As the solution comes in contact with 
gelation solution, it was immediately converted into 
stiff gel like structure. The gelling capacity of 
solution was evaluated on the basis of stiffness of 
formed gel and time period for which the formed gel 
remains as such. Color was added to give visualized 
appearance to formed gel. The in-vitro gelling 
capacity was graded in three categories on the basis of 
gelation time and time period for which the formed 
gel remains5.  
 
  (+)     Gels after few minutes, dispersed rapidly 
  (++)   Gelation immediate remains for few hours 
  (+++) Gelation immediate remains for an 
extended period 
 
 
 
Figure 5: Overlapping spectra of Q1, Q12 & T80% 
for CLR 
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5. In-vitro floating ability 
The in-vitro floating study was carried out using 0.1N 
HCl, (pH 1.2) .The medium temperature was kept at 
37oC. Ten milliliter formulation was introduced into 
the dissolution vessel containing medium without 
much disturbance. The time the formulation took to 
emerge on the medium surface (floating lag time) and 
the time the formulation constantly floated on surface 
of the dissolution medium (duration of floating) were 
noted6. 
 
 
Figure 6: In-vitro release profile of CLR of Batches 
F1 to F9 
 
6. In-vitro drug release study 
The release rate of CLR & MTB from sustained 
release suspension was determined using USP XXIV 
dissolution testing apparatus I (basket covered with 
muslin cloth) at 50 rpm. This speed was slow enough 
to avoid the breaking of gelled formulation and was 
maintaining the mild agitation conditions believed to 
exist in vivo. The dissolution medium used was 900 
ml of 0.1 N HCl, and temperature was maintained at 
37oC. A sample (five ml) of the solution was 
withdrawn from the dissolution apparatus at 
1,2,4,6,8,10 &12 hrs of dissolution. The samples were 
filtered through 0.45µ membrane filter and analyzed 
using HPLC method. Cumulative % of drug release 
was calculated & observations are shown in tables7-9.   
 
7. Accelerated stability study of Check Point batch   
Clarithromycin & Metronidazole benzoate SR 
suspension were first packed in glass bottles (well 
stoppered) and then packing forms were kept for three 
months and the stability of the suspension was 
monitored up to 3 months at accelerated stability 
conditions (45 ºC temperature and 75 + 5% RH). 
Periodically (initial, 1, 2 and 3 months interval) 
samples were removed and characterized by pH, 
viscosity, %assay, in-vitro gelling capacity, floating 
lag time, total floating time and in-vitro drug release 
study. The similarity factor (f2) was applied to study 
the effect of storage on check point batch10,11.  
 
 
 
Figure 7: Contour plot showing effect of X1 and X2 
on Q1 for MTB 
 
Result & discussion 
1. DSC study 
From the above DSC Study and physical observation 
we have concluded that there was no significant 
Drug- Excipient interaction was observed. From DSC 
study, we can show that there is no change in drug’s 
melting peak. So we can conclude that drugs and 
other excipients are compatible which each other as 
per shown in Figure 1. 
 
2. Optimization of CLR & MTB SR Suspension 
using 32 full factorial designs 
2.1 For CLR 
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(A) Effect of formulation variable on CPR at 1 hr 
(Q1) 
Concerning Q1, the results of multiple linear 
regression analysis showed that both the coefficients 
b1 and b2 bear a negative sign. The fitted equation 
relating the response Q1 to the transformed factor is 
shown in following equation, 
Q1 = 25.198 -1.825 X1 -0.017X2 + 0.0175 X1X2 – 
0.168 X12 + 0.206 X22  
 
 (R2 = 0.9730)                                      ……… (2) 
 
The Q1 for all batches F1 to F9 shows good 
correlation co-efficient of 0.9730. From table 2, 
Variable X1 has p value 0.002743(p<0.05) & variable 
X2 has p value 0.0165(p<0.05). Variables which have 
p value less than 0.05, significantly affect the release 
profile. It is possible that at higher polymers 
concentration, drug is trapped in smaller polymer 
cells and it is structured by its close proximity to the 
polymer molecules. So, increasing the amount of the 
polymer in the formulations increased the time it took 
for the drug to leave the formulation and retard 
release of drug into the medium. 
 
Table 2: Summary output of Regression analysis of CLR for effect of X1 & X2 on Q1, Q12 and T80% 
 
 Q1 Q12 T80% 
Multiple R 0.986445 0.996427 0.995913 
R2 0.973074 0.992867 0.991842 
Adjusted R2 0.928197 0.980979 0.978246 
Standard error 0.487563 0.376965 0.053576 
 
 
 
Regression  
Statistics 
Observations 9 9 9 
 
Coefficient 
value P-value 
Coefficient 
value P-value 
Coefficient 
value P-value 
b0 25.19889 6.61E-06 97.84 5.22E-08 9.355556 1.71E-07 
b1 -1.825 0.002743 -2.225 0.000717 0.316667 0.00072 
b2 -0.97 0.016513 -1.78667 0.001373 0.266667 0.00119 
 
 
 
Coefficients 
b12 0.0175 0.94729 -1.1775 0.008274 -0.025 0.41953 
 
Equations 
Q1 = 25.198 – 1.825(X1) -
0.017 (X2) + 0.0175X1X2 
Q12= 97.84 – 2.225(X1) – 
1.786 (X2) – 1.177X1X2 
T80%= 9.355 + 0.316 (X1) + 
0.266 (X2) – 0.025X1X2 
 
The relationship between formulation variables (X1 
and X2) and Q1 was further elucidated using contour 
plot. The effects of X1 and X2 on Q1 are given in 
Figure 2. At highest levels of X2, Q1 decreased from 
28.3% to 22.29% when X1 was increased from -1 
level to the +1 level.  
 
Table 3: Summary output of Regression analysis of MTB for effect of X1 & X2 on Q1, Q12 and T80% 
 
 Q1 Q12 T80% 
Multiple R 0.985212 0.993711 0.98622 
R2 0.970643 0.987462 0.972629 
Adjusted R2 0.921716 0.966566 0.927011 
Standard error 0.627682 0.504519 0.10844 
 
 
 
Regression  
Statistics 
Observations 9 9 9 
 
Coefficient 
value P-value 
Coefficient 
value P-value 
Coefficient 
value P-value 
b0 31.42556 7.27E-06 97.77778 1.25E-07 9.155556 0.00152 
b1 -2.23 0.003194 -2.31667 0.001507 0.35 0.00422 
b2 -1.21333 0.017858 -1.745 0.003452 0.283333 0.00773 
 
 
 
Coefficients 
b12 0.0225 0.947359 -1.0675 0.024145 -0.075 0.26055 
 
Equations 
Q1 = 31.425 – 2.23(X1) – 
1.213(X2) + 0.0225X1X2 
Q12= 97.777 – 2.316(X1) – 
1.745(X2) – 1.067X1X2 
T80%= 9.155 + 0.35(X1) 
0.283(X2) – 0.075X1X2 
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The amount of drug released at the end of 12 hrs is 
also important parameter for prominent drug release 
from sustained release matrix formulation. 
Concerning Q12, the results of multiple linear 
regression analysis showed that, coefficients b1 and 
b2, as well as interaction term b12 bear a negative sign. 
The fitted equation relating the response Q20 to the 
transformed factor is shown in following equation, 
Q12 = 97.84 – 2.225 X1– 1.786 X2 – 1.177 X1X2– 
1.565 X11– 0.14 X22 
 
 (R2= 0.9928)                                                 ……. (3) 
 
The Q12 for all batches F1 to F9 shows good 
correlation co-efficient of 0.9928. From table 2, 
Variable X1 has p value 0.0007 (p<0.05), variable X2 
has p value 0.0013 (p<0.05) & the interaction term 
b12 has p value 0.0082 (p<0.05). Variables which 
have p value less than 0.05, significantly affect the 
release profile. 
 
 
 
Figure 8: Contour plot showing effect of X1 and X2 
on Q12 for MTB 
 
(B) Effect of formulation variable on CPR at 12 hr 
(Q12) 
The relationship between formulation variables (X1 
and X2) and Q12 is further elucidated using contour 
plot. The effects of X1 and X2 on Q12 are given in 
Figure 3 at highest levels of X2, Y2 decreased from 
98.87% to 91.2% when X1 was increased from -1 
level to the +1 level.  
 
 
 
 
Figure 9: Contour plot showing effect of X1 and X2 
on T80% for MTB 
 
(C) Effect of formulation variable on T80% 
The time required for 80% of the drug release is an 
important parameter, for prominent drug release from 
sustain release matrix formulation.  
In the case of T80%, Variable X1 & X2 are found to be 
significant based on its P-value (p<0.05), from Table 
2. The results showed in Table 2 revels that, when the 
concentration of Sodium alginate (X1) & 
concentration of HPMC K 100M (X2) was increased, 
T80 was increased.  
T80%   = 9.355 + 0.316 X1+ 0.266 X2 – 0.025 X1X2– 
0.083 X11– 0.033 X22 
 
 (R2= 0.9918)                                                  ……. (4) 
 
The relationship between formulation variables (X1 
and X2) and T80 was further elucidated using contour 
plot. The effects of X1 and X2 on T80 are given in 
Figure 4. At highest levels of X2, T80 increased from 
8.6 hr. to 9.8 hr. when X1 was increased from -1 level 
to the +1 level.  
 
2.2. For MTB 
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(A) Effect of formulation variable on CPR at 1 hr 
(Q1) 
Concerning Q1, the results of multiple linear 
regression analysis showed that both the coefficients 
b1 and b2 bear a negative sign. The fitted equation 
relating the response Q1 to the transformed factor is 
shown in following equation, 
Q1 = 31.425 -2.23 X1 – 1.213 X2 + 0.022 X1X2 – 
0.263 X12 + 0.366 X22  
 
 (R2 = 0.9706)                                          ……… (5) 
 
The Q1 for all batches F1 to F9 shows good 
correlation co-efficient of 0.9706. From table 3, 
Variable X1 has p value 0.00319(p<0.05) & variable 
X2 has p value 0.0178(p<0.05). Variables which have 
p value less than 0.05, significantly affect the release 
profile. This finding was probably due to the 
increased strength of the formed gel structure. It is 
worthwhile to remember that the drug diffusion is 
controlled by the penetration of liquid through the gel 
structure 
 
 
 
Figure 10: Overlapping spectra of Q1, Q12 & T80% 
for MTB 
 
It is possible that at higher polymers concentration, 
drug is trapped in polymer cells and it is structured by 
its close proximity to the polymer molecules. So 
increasing the amount of the polymer in the 
formulations increased the time it took for the drug to 
leave the formulation and retard release of drug into 
the medium. 
  
(B) Effect of formulation variable on CPR at 12 hr 
(Q12) 
The relationship between formulation variables (X1 
and X2) and Q1 was further elucidated using contour 
plot. The effects of X1 and X2 on Q1 are given in 
Figure 7. At highest levels of X2, Q1 decreased from 
35.38% to 27.86% when X1 was increased from -1 
level to the +1 level.  
The amount of drug released at the end of 12 hrs is 
also important parameter for prominent drug release 
from sustained release matrix formulation. 
Concerning Q12, the results of multiple linear 
regression analysis showed that coefficients b1 and b2, 
as well as interaction term b12 bear a negative sign. 
The fitted equation relating the response Q12 to the 
transformed factor is shown in following equation, 
Q12 = 97.77 – 2.316 X1– 1.745 X2 – 1.067 X1X2– 
1.596 X11– 0.081 X22 
 
 (R2= 0.9874)                                              ……. (6) 
 
 
Figure 11: In-vitro release profile of MTB of 
Batches F1 to F9 
 
The Q12 for all batches F1 to F9 shows good 
correlation co-efficient of 0.9874. From table 3, 
Variable X1 has p value 0.0015 (p<0.05), variable X2 
has p value 0.0034 (p<0.05) & the interaction term 
b12 has p value 0.024 (p<0.05). Variables which have 
p value less than 0.05, significantly affect the release 
profile. 
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Table 4: Evaluation of Batches F1 to F9 
 
Batch 
Code 
Viscosity 
(cps) 
pH % Assay of 
CLR 
% Assay 
MTB 
Gelling 
in 0.1N 
HCL 
Duration of 
floating 
(hours) 
F1 148 7.2 97.89+0.63 97.74+0.63% + < 9 
F2 151 7.2 98.03+0.42 98.01+0.31% ++ < 11 
F3 154 7.3 98.01+0.15 97.87+0.13% +++ > 12 
F4 158 7.4 98.07+1.05 98.12+1.3%, ++ > 12 
F5 162 7.6 99.52+0.42 101.43+0.41% +++ > 12 
F6 168 7.7 100.06+0.12 99.27+0.24% +++ > 12 
F7 176 7.8 99.85+0.21 100.14+0.11% +++ > 12 
F8 187 7.5 99.63+0.17 99.36+0.32% +++ > 12 
F9 194 7.8 98.84+0.63 98.85+0.62% +++ > 12 
 
Note: Spindle LV1, Speed: 10 RPM, Temperature: 25 ± 1oC, (+), gels after few minutes, dispersed 
rapidly; (++), gelation immediate, remains for few hours;  (+++), gelation immediate, remains for 
an extended period 
 
The relationship between formulation variables (X1 
and X2) and Q12 is further elucidated using contour 
plot. The effects of X1 and X2 on Q12 are given in 
Figure 8. At highest levels of X2, Y2 decreased from 
98.91% to 91.33% when X1 was increased from -1 
level to the +1 level.  
 
 
Table 5: Evaluation of Accelerated Stability study of Check point batch 
 
Time period for sampling Evaluation parameters 
Initial 1 month 2 month 3 month 
pH 7.8 7.8 7.78 7.78 
Viscosity (cps) 167 167 167 168 
In-vitro gelling capacity +++  +++  +++  +++  
Floating lag time (min) <1 <1 <1 <1 
Total floating time (hr) >12 >12 >12 >12 
% assay (Clarithromycin) 99.27+0.23 99.21+0.14 99.23+0.25 99.2+0.41 
%assay (Metronidazole 
benzoate) 
99.56+0.21 99.54+0.19 99.53+0.31 99.51+0.36 
 
(C) Effect of formulation variable on T80% 
The time required for 80% of the drug release is an 
important parameter for prominent drug release from 
sustained release matrix formulation.  
In the case of T80%, Variable X1 & X2 are found to be 
significant based on its P-value (p<0.05) (Table 3). 
The results showed in Table 1 revels that, when the 
concentration of Sodium alginate (X1) & 
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concentration of HPMC K 100M (X2) was increased, 
T80 was increased.  
 
T80%   = 9.155 + 0.35 X1+ 0.283 X2 – 0.075 X1X2– 
0.083 X11 + 0.0167 X22 
 
 (R2= 0.9726)                                                  ……. (7) 
 
The relationship between formulation variables (X1 
and X2) and T80 was further elucidated using contour 
plot. The effects of X1 and X2 on T80 are given in 
Figure 9. At highest levels of X2, T80 increased from 
8.3 hr. to 9.7 hr. when X1 was increased from -1 level 
to the +1 level.  
 
3. Evaluation of 32 full factorial design formulation 
batches 
3.1 Viscosity profile 
The results of viscosity measurement of the 
formulations of batches F1 – F9 are shown in Table 4. 
The order of viscosity of all formulations was F9 > F8 
> F7 > F6 > F5 > F4 > F3 > F2 > F1 respectively. The 
formulations showed a marked increase in viscosity 
with increasing concentration of sodium alginate and 
HPMC k100M. 
 
 
 
Figure 12: In-vitro release profile of CLR before 
and after stability 
 
3.2  pH Measurement 
The pH of all the formulations was observed in the 
range of 7.2 – 7.8 (Table 4). It is well documented 
that within this pH range Metronidazole benzoate as 
well as preservatives (Methyl paraben and Propyl 
paraben) retain their activity. Therefore, there was no 
need for pH adjustment by any external alkalizing 
agent. 
 
3.3 Drug content 
This is one of an important requirement for any type 
of dosage form. Amount of the drug present in the 
formulation should not deviate beyond certain 
specified limits from the labeled amount (Table 4). 
 
3.4 In-vitro gelling capacity 
The two main pre-requisites of in situ gelling systems 
are optimum viscosity and gelling capacity (speed and 
extent of gelation). The formulation should have an 
optimum viscosity that will allow easy swallowing as 
a liquid, which then undergoes a rapid sol–gel 
transition due to ionic interaction. Moreover, the in 
situ formed gel should preserve its integrity without 
dissolving or eroding for prolonged period to 
facilitate sustained release of drugs locally. Sol to gel 
transformation of sodium alginate occurs in the 
presence of either monovalent or divalent cations in 
contact with the gastric fluids. The calcium carbonate 
present in the formulation as insoluble dispersion is 
dissolved and releases carbon dioxide on reaction 
with acid, and the in situ released calcium ions results 
in formation of gel with floating characteristics. It is 
established that formulations containing calcium 
carbonate produce containing sodium bicarbonate. 
This is due to the internal ionotropic gelation effect of 
calcium on sodium alginate. 
 
3.5 In-vitro floating ability 
The time taken by the formulation to emerge on the 
medium surface (floating lag time) and the time for 
which the formulation constantly floated on the 
dissolution medium surface (duration of floating) are 
shown in Table 4. 
The released carbon dioxide is entrapped in the gel 
network producing buoyant formulation and then 
calcium ion reacted with sodium alginate produced a 
cross-linked three-dimensional gel network  and 
swelled structure of HPMC K100M that might restrict 
the further diffusion of carbon dioxide and drug 
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molecules and has resulted in extended period of 
floating and drug release respectively. 
 
 
Figure 13: In-vitro release profile of MTB before 
& after stability 
 
3.6 In-vitro drug release 
The effect of polymer concentration on in-vitrodrug 
release from in situ gels is shown in Figure 6 & 
Figure 11. A significant  decrease in the rate and 
extent of drug release was observed with  the increase 
in polymer concentration and is attributed to increase 
in the density of the polymer matrix and also an 
increase in the diffusional path length which the drug 
molecules have to traverse. The relsease of drug from 
these gels was characterized by an initial phase of 
high release (burst effect). However, as gelation 
proceeds, the remaining drug was released at a slower 
rate followed by a second phase of moderate release. 
This bi-phasic pattern of release is a characteristic 
feature of matrix diffusion kinetics. The initial burst 
effect was considerably reduced with increase in 
polymer concentration. 
 
7. Stability study 
Sample withdrawn at the interval of one month for 
three months showed no change in in-vitro drug 
release profile (Figure 12 & 13).  Results of the 
stability study show no remarkable change in the 
release profile, assay and other evaluation parameters 
of the CLR & MTB SR suspension after the stability. 
 
Conclusion 
In formulation CLR & MTB SR suspension, a 32 full 
factorial design was employed for preparation of 
suspension possessing optimized characteristics 
(batches F1 to F9). The amount of Sodium alginate 
(X1) and HPMC K-4M (X2) were selected as 
independent variables. Cumulative % drug release 
selected as dependent variable (response; Y). Based 
on result of multiple linear regression analysis, it was 
concluded that both variables significantly affect the 
release profile at Q1, Q12 and T80. So role of polymer 
concentration is very important in this formulation. 
From DSC study, we can show that there is no change 
in drug’s melting peak. So, we can conclude that drug 
and other excipient are compatible which each other. 
Stability study of Check point batch after three month 
showed no change in in-vitro drug release profile, % 
assay and other evaluation parameters. It was 
concluded that by adopting a systematic formulation 
approach, an optimum point could be reached in the 
shortest time with minimum efforts. 
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